Navigation Links
Researchers Try Early Surgical Intervention to Treat Parkinson's Symptoms

Researchers at Vanderbilt University Medical Center are attempting to short circuit the progression of Parkinson's disease by implanting stimulation devices //into the brains of Parkinson's patients earlier on in the course of their disease.

'One of the driving theories behind this study is the possibility that if deep brain stimulation (DBS) therapy was applied early, it may change the progression of the disease, hopefully slowing its advance,' said David Charles, M.D., vice-chair of Neurology and director of the Vanderbilt Movement Disorders Clinic.

Charles says to date there is no current therapy that has been proven to definitely slow the progression of Parkinson's disease. Vanderbilt's Phase 1 clinical trial — the first of its kind in the world — was years in development and just recently received Food and Drug Administration (FDA) approval to begin.

Parkinson's disease is a chronic, debilitating neuromuscular disease caused by the brain's inability to produce a sufficient amount of the chemical dopamine, which in turn causes nerve cell death leading to impaired function of the body's muscles and movement.

Key symptoms of Parkinson's are tremor (shaking), difficulty with balance, slowness of movement, and rigidity. Other symptoms can include stiff facial expression, shuffling walk, muffled speech and depression.

The National Institutes of Health (NIH) estimates there are as many as 500,000 U.S. citizens with Parkinson's disease, and others, such as the Parkinson's Disease Foundation, say it is more prevalent and may affect as many as 1 million Americans. Estimates are as many as 50,000 new cases are diagnosed each year.

“The theory that applying this therapy early in the course of Parkinson's is that we may see a difference,” Charles said.

Vanderbilt researchers hope that by providing a treatment now only offered in late-stage Parkinson's, they can slow the disease's typical prog ression.

“For this study, which is to measure safety and tolerability of the device in these patients, we'll be using DBS the same way we're treating advanced patients, only much earlier,” Charles said.

“We hope to obtain preliminary data that will tell us whether a larger trial is warranted.”

The study's protocol calls for a small number of patients to be enrolled and followed over a four-year period.

“If this proves successful we hope to launch a larger trial in the future to test the question of whether this therapy can change or slow the progression of Parkinson's disease,” he said.

In 1996 VUMC became one of the first centers in the United States to implant stimulators into the brains of Parkinson's disease patients with advanced symptoms.

DBS is a device which emits a continuous, tunable electrical current, attached to a fine wire, that runs from the unit and is carefully implanted into a specific location deep within the brain. When activated, the DBS device acts on the subthalamic nucleus with electrical stimulation to reduce the symptoms of Parkinson's. In many patients the device produces dramatic results.

Charles and other researchers in Vanderbilt's Departments of Neurology and Neurosurgery have devoted a significant portion of their academic careers to research to find better ways to slow disease progression and improve symptoms of Parkinson's patients. VUMC has been one of the nation's leading centers in Parkinson's research for more than 20 years.

“Our experience has found if patients who receive DBS are properly selected they typically can reduce medicines by about 25 percent. Afterward they can extend the period of time they have a positive impact from their medicine by about 50 percent,” Charles said. “So the impact on their overall condition is very good.”

Charles said trial participants may help advance the field of research in Parkinson's disease.

“What we learn in this trial will really shape the next step of research on this disease. We are trying to answer a major question of whether receiving this therapy early in the disease may slow progression. If this were to prove true there is no other therapy we can offer today which can do that,” he said.

(Souce: Newswise)
'"/>




Related medicine news :

1. Researchers urge caution in using ear tube surgery
2. Researchers Scale to assess the Severity of Epilepsy in Kids
3. Researchers trick Alzheimers Enzyme
4. Researchers find new HIV hiding place
5. New Hair in 15 Days Could Now Be A Possibility Say Researchers
6. Researchers developed world’s smallest toothbrus
7. Researchers discover receptor cells that can cause epilepsy
8. 15 Anti-SARS Drugs Identified By China-Europe Team of Researchers
9. Researchers reversed the process of memory loss
10. Researchers Identify Key Gene That May Help Brain Treatment
11. Researchers Discover Protein That Causes Malaria
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:5/27/2017)... ... May 27, 2017 , ... In any business, follow up is critical to ... dental team at presenting treatment, there will always be some patients who can’t or ... money on best practices when it comes to presenting treatment. After the patient ...
(Date:5/26/2017)... ... 26, 2017 , ... Leading CEOs from biotech, pharmaceutical, and ... 31st at The Four Seasons Hotel Boston. , The Boston CEO Conference ... exclusive access to key decision makers who influence deal making and investment. Attendees ...
(Date:5/26/2017)... (PRWEB) , ... May 26, 2017 , ... ... premium delicatessen foods, is sharing bold recipes for Memorial Day entertaining that are ... menus. , “Boar’s Head fresh sliced meats and cheeses featured in these ...
(Date:5/26/2017)... ... May 26, 2017 , ... Silver Birch of Hammond, a new assisted lifestyle ... than four acres of land at 5620 Sohl Avenue in Hammond, serves older adults ... includes 125 studio and one-bedroom apartments. Each of the private apartments at Silver Birch ...
(Date:5/26/2017)... ... May 26, 2017 , ... Centennial-based BluSky Restoration Contractors announced ... 14th Annual Clays for Kids fundraiser, to be held Friday, Sept. 22, at ... As part of BluSky’s partnership with The Adoption Exchange, BluSky will also share ...
Breaking Medicine News(10 mins):
(Date:5/9/2017)... 9, 2017  Oramed Pharmaceuticals Inc. (NASDAQ: ... pharmaceutical company focused on the development of oral ... Intellectual Property Office has granted Oramed a patent ... Exenatide". The patent covers Oramed,s invention of an ... is an incretin hormone that stimulates the secretion ...
(Date:5/6/2017)... Provista , a proven leader in the supply chain industry ... Jim Cunniff as the company,s new president and CEO. ... Provista, including most recently serving as the president and CEO ... He assumed his new role with Provista on May 1, ... says Jody Hatcher , president, Sourcing and Collaboration Services ...
(Date:5/4/2017)... 2017  A recent study published in the ... light as a means of disinfection anesthesia workstations ... bioburden on anesthesia workstations. In the study, UVC ... medical equipment surfaces contaminated with three (3) organisms ... study further validates the body of literature supporting ...
Breaking Medicine Technology: